BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao X, Qureshi F, Eastman PS, Manning WC, Alexander C, Robinson WH, Hesterberg LK. Pre-analytical effects of blood sampling and handling in quantitative immunoassays for rheumatoid arthritis. J Immunol Methods 2012;378:72-80. [PMID: 22366959 DOI: 10.1016/j.jim.2012.02.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Chernoff D, Scott Eastman P, Hwang CC, Flake DD 2nd, Wang X, Kivitz A, Curtis JR. Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores. Clin Rheumatol 2019;38:437-45. [PMID: 30159791 DOI: 10.1007/s10067-018-4276-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Khan MU, Bowsher RR, Cameron M, Devanarayan V, Keller S, King L, Lee J, Morimoto A, Rhyne P, Stephen L, Wu Y, Wyant T, Lachno DR. Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. Bioanalysis 2015;7:229-42. [DOI: 10.4155/bio.14.274] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
3 Davis JM 3rd. Editorial: The Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis: Is It a Valid Measure of Disease Activity? Arthritis Rheumatol 2016;68:2061-6. [PMID: 27111349 DOI: 10.1002/art.39716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm 2014;2014:545493. [PMID: 24733962 DOI: 10.1155/2014/545493] [Cited by in Crossref: 69] [Cited by in F6Publishing: 86] [Article Influence: 8.6] [Reference Citation Analysis]
5 Gupta V, Davancaze T, Good J, Kalia N, Anderson M, Wallin JJ, Brady A, Song A, Xu W. Bioanalytical qualification of clinical biomarker assays in plasma using a novel multi-analyte Simple Plex platform. Bioanalysis 2016;8:2415-28. [DOI: 10.4155/bio-2016-0196] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
6 Ray S, Patel SK, Kumar V, Damahe J, Srivastava S. Differential expression of serum/plasma proteins in various infectious diseases: specific or nonspecific signatures. Proteomics Clin Appl 2014;8:53-72. [PMID: 24293340 DOI: 10.1002/prca.201300074] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
7 Ilies M, Iuga CA, Loghin F, Dhople VM, Thiele T, Völker U, Hammer E. Impact of blood sample collection methods on blood protein profiling studies. Clinica Chimica Acta 2017;471:128-34. [DOI: 10.1016/j.cca.2017.05.030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
8 Peabody JW, Strand V, Shimkhada R, Lee R, Chernoff D. Impact of rheumatoid arthritis disease activity test on clinical practice. PLoS One 2013;8:e63215. [PMID: 23667587 DOI: 10.1371/journal.pone.0063215] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
9 Roubroeks JAY, Smith AR, Smith RG, Pishva E, Ibrahim Z, Sattlecker M, Hannon EJ, Kłoszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Wahlund LO, Aarsland D, Proitsi P, Hodges A, Lovestone S, Newhouse SJ, Dobson RJB, Mill J, van den Hove DLA, Lunnon K. An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiol Aging 2020;95:26-45. [PMID: 32745807 DOI: 10.1016/j.neurobiolaging.2020.06.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
10 Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, Alexander C, Hesterberg LK. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. Journal of Pharmaceutical and Biomedical Analysis 2012;70:415-24. [DOI: 10.1016/j.jpba.2012.06.003] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
11 Rosskopf S, Gyurján I, Soldo R, Luna-Coronell JA, Vierlinger K, Singer CF, Rappaport C, Pecha N, Weinhaeusel A. The pre-analytical processing of blood samples for detecting biomarkers on protein microarrays. J Immunol Methods 2015;418:39-51. [PMID: 25675867 DOI: 10.1016/j.jim.2015.01.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
12 Riis JL, Ahmadi H, Hamilton KR, Hand T, Granger DA. Best practice recommendations for the measurement and interpretation of salivary proinflammatory cytokines in biobehavioral research. Brain Behav Immun 2021;91:105-16. [PMID: 32931871 DOI: 10.1016/j.bbi.2020.09.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Birse CE, Tomic JL, Pass HI, Rom WN, Lagier RJ. Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules. Clin Proteomics 2017;14:25. [PMID: 28694742 DOI: 10.1186/s12014-017-9158-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
14 Ilies M, Iuga CA, Loghin F, Dhople VM, Hammer E. Plasma protein absolute quantification by nano-LC Q-TOF UDMSE for clinical biomarker verification. Clujul Med 2017;90:425-30. [PMID: 29151793 DOI: 10.15386/cjmed-880] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Johnson TM, Register KA, Schmidt CM, O'Dell JR, Mikuls TR, Michaud K, England BR. Correlation of the Multi-Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken) 2019;71:1459-72. [PMID: 30320973 DOI: 10.1002/acr.23785] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
16 Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, Goodman MT, Tait JF, Tewari M, Pritchard CC. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One. 2013;8:e64795. [PMID: 23762257 DOI: 10.1371/journal.pone.0064795] [Cited by in Crossref: 194] [Cited by in F6Publishing: 189] [Article Influence: 21.6] [Reference Citation Analysis]
17 Kaisar M, van Dullemen LFA, Thézénas ML, Zeeshan Akhtar M, Huang H, Rendel S, Charles PD, Fischer R, Ploeg RJ, Kessler BM. Plasma degradome affected by variable storage of human blood. Clin Proteomics 2016;13:26. [PMID: 27708557 DOI: 10.1186/s12014-016-9126-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
18 Felgate C, Spooner N, Calloway R. An investigation of the comparability of commercially sourced plasma and pharmaceutical study plasma, using total protein concentration. Bioanalysis 2016;8:311-21. [PMID: 26808091 DOI: 10.4155/bio.15.248] [Reference Citation Analysis]
19 Macagno A, Athanasiou A, Wittig A, Huber R, Weber S, Keller T, Rhiel M, Golding B, Schiess R. Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer. PLoS One 2020;15:e0233442. [PMID: 32421745 DOI: 10.1371/journal.pone.0233442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Lima-Oliveira G, Monneret D, Guerber F, Guidi GC. Sample management for clinical biochemistry assays: Are serum and plasma interchangeable specimens? Crit Rev Clin Lab Sci 2018;55:480-500. [PMID: 30309270 DOI: 10.1080/10408363.2018.1499708] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
21 Parker CE, Borchers CH. Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays. Mol Oncol. 2014;8:840-858. [PMID: 24713096 DOI: 10.1016/j.molonc.2014.03.006] [Cited by in Crossref: 139] [Cited by in F6Publishing: 126] [Article Influence: 17.4] [Reference Citation Analysis]